A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Trial Details

NCT ID
NCT07174583
Phase
PHASE1 / PHASE2
Sponsor
IDEAYA Biosciences
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • IDE849
  • durvalumab
  • IDE161
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Orlando, Florida, United States|28.53834,-81.37924
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Are willing to participate in this clinical study, understand the study procedures, and are able to sign the written ICF.
  • Subjects with histologically or cytologically confirmed extensive-stage SCLC neuroendocrine carcinoma (NEC), and other DLL3+ tumors, are eligible p…
  • Subjects will be required to provide blood/tumor tissue samples for biomarker testing.
  • Have at least 1 measurable lesion according to RECIST version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →